Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1924 1
1938 1
1939 5
1940 1
1941 1
1942 1
1946 2
1947 3
1948 5
1949 2
1950 12
1951 13
1952 35
1953 21
1954 9
1955 12
1956 9
1957 22
1958 17
1959 21
1960 11
1961 13
1962 28
1963 48
1964 34
1965 42
1966 43
1967 40
1968 32
1969 40
1970 41
1971 40
1972 55
1973 60
1974 64
1975 61
1976 94
1977 84
1978 89
1979 125
1980 140
1981 169
1982 222
1983 209
1984 259
1985 294
1986 311
1987 384
1988 394
1989 428
1990 523
1991 574
1992 633
1993 752
1994 826
1995 980
1996 1115
1997 1330
1998 1483
1999 1833
2000 2161
2001 2500
2002 2988
2003 3492
2004 4170
2005 5046
2006 5805
2007 6345
2008 7424
2009 8177
2010 9260
2011 10529
2012 12067
2013 13224
2014 14815
2015 15946
2016 16946
2017 18083
2018 19806
2019 22507
2020 26050
2021 10178
Text availability
Article attribute
Article type
Publication date

Search Results

226,183 results
Results by year
Filters applied: . Clear all The following term was not found in PubMed: Yu-Tsang
Page 1
Did you mean yu tsung lu (1 results)?
MiR-20a regulates fibroblast-like synoviocyte proliferation and apoptosis in rheumatoid arthritis.
Wei XJ, Li XW, Lu JL, Long ZX, Liang JQ, Wei SB, Lu CX, Lu WZ. Wei XJ, et al. Eur Rev Med Pharmacol Sci. 2020 Jul;24(14):7578. doi: 10.26355/eurrev_202007_22253. Eur Rev Med Pharmacol Sci. 2020. PMID: 32744683
Since this article has been suspected of research misconduct and the corresponding authors did not respond to our request to prove originality of data and figures, "MiR-20a regulates fibroblast-like synoviocyte proliferation and apoptosis in rheumatoid arthritis, by X.-J. Wei, X. …
Since this article has been suspected of research misconduct and the corresponding authors did not respond to our request to prove originali …
Radioligand therapy using [(177)Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis.
Seifert R, Kessel K, Schlack K, Weckesser M, Bögemann M, Rahbar K. Seifert R, et al. Eur J Nucl Med Mol Imaging. 2020 Aug;47(9):2106-2112. doi: 10.1007/s00259-020-04703-3. Epub 2020 Feb 16. Eur J Nucl Med Mol Imaging. 2020. PMID: 32062682 Free PMC article.
Various studies have evaluated the efficacy and safety of [(177)Lu]Lu-PSMA-617 using a dose of 6.0 GBq and an 8-week therapy interval. ...However, future studies are needed to elucidate the dose-related efficacy of [(177)Lu]Lu-PSMA-617 as a way to pers …
Various studies have evaluated the efficacy and safety of [(177)Lu]Lu-PSMA-617 using a dose of 6.0 GBq and an 8-week therapy i …
Effects of adding an albumin binder chain on [(177)Lu]Lu-DOTATATE.
Rousseau E, Lau J, Zhang Z, Uribe CF, Kuo HT, Zhang C, Zeisler J, Colpo N, Lin KS, Bénard F. Rousseau E, et al. Nucl Med Biol. 2018 Nov;66:10-17. doi: 10.1016/j.nucmedbio.2018.08.001. Epub 2018 Aug 9. Nucl Med Biol. 2018. PMID: 30170196
In vivo, [(177)Lu]Lu-GluAB-DOTATATE and [(177)Lu]Lu-AspAB-DOTATATE had significantly higher blood activity at 1, 4 and 24 h compared to [(177)Lu]Lu-DOTATATE. ...Renal uptake was 7.49 1.62%ID/g for [(177)Lu]Lu-DOTATATE, 31.14 …
In vivo, [(177)Lu]Lu-GluAB-DOTATATE and [(177)Lu]Lu-AspAB-DOTATATE had significantly higher blood activity at 1, …
Modelling of the (177m)Lu/(177)Lu radionuclide generator.
Bhardwaj R, Wolterbeek HT, Denkova AG, Serra-Crespo P. Bhardwaj R, et al. Appl Radiat Isot. 2020 Dec;166:109261. doi: 10.1016/j.apradiso.2020.109261. Epub 2020 Jul 10. Appl Radiat Isot. 2020. PMID: 32961525 Free article.
In order to determine the potential of (177m)Lu/(177)Lu radionuclide generator in (177)Lu production it is important to establish the technical needs that can lead to a clinically acceptable (177)Lu product quality. ...The dissociation rate constants l …
In order to determine the potential of (177m)Lu/(177)Lu radionuclide generator in (177)Lu production it is important to …
Comparison of biological properties of [(177) Lu]Lu-ProBOMB1 and [(177) Lu]Lu-NeoBOMB1 for GRPR targeting.
Rousseau E, Lau J, Zhang Z, Zhang C, Kwon D, Uribe CF, Kuo HT, Zeisler J, Bratanovic I, Lin KS, Bénard F. Rousseau E, et al. J Labelled Comp Radiopharm. 2020 Feb;63(2):56-64. doi: 10.1002/jlcr.3815. Epub 2020 Jan 11. J Labelled Comp Radiopharm. 2020. PMID: 31715025
Lu-NeoBOMB1 had better binding affinity for GRPR than Lu-ProBOMB1 (K(i) values: 2.26 0.24 and 30.2 3.23nM). [(177) Lu]Lu-ProBOMB1 was obtained in 53.7 5.4% decay-corrected radiochemical yield with 444.2 193.2 GBq/mumol molar activity and >95% radioc
Lu-NeoBOMB1 had better binding affinity for GRPR than Lu-ProBOMB1 (K(i) values: 2.26 0.24 and 30.2 3.23nM). [(177) Lu]
(177)Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy.
Banerjee SR, Kumar V, Lisok A, Chen J, Minn I, Brummet M, Boinapally S, Cole M, Ngen E, Wharram B, Brayton C, Hobbs RF, Pomper MG. Banerjee SR, et al. Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2545-2557. doi: 10.1007/s00259-019-04434-0. Epub 2019 Aug 10. Eur J Nucl Med Mol Imaging. 2019. PMID: 31399803
Efficacy and toxicity after 8 weeks were evaluated at a single administration of 111 MBq for (177)Lu-L1, (177)Lu-L3, (177)Lu-L5 and (177)Lu-PSMA-617. Efficacy of (177)Lu-L1 was further investigated using different doses, and long-term toxicity w …
Efficacy and toxicity after 8 weeks were evaluated at a single administration of 111 MBq for (177)Lu-L1, (177)Lu-L3, (177)L
Biodistribution, Pharmacokinetics, and Dosimetry of (177)Lu-, (90)Y-, and (111)In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist (177)Lu-DOTATATE: The Mass Effect.
Nicolas GP, Mansi R, McDougall L, Kaufmann J, Bouterfa H, Wild D, Fani M. Nicolas GP, et al. J Nucl Med. 2017 Sep;58(9):1435-1441. doi: 10.2967/jnumed.117.191684. Epub 2017 Apr 27. J Nucl Med. 2017. PMID: 28450554 Free article.
In this preclinical study, the SSTR2 antagonist OPS201 (DOTA-JR11; DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH(2)]) labeled with (177)Lu, (90)Y, and (111)In was compared with the SSTR2 agonist (177)Lu-DOTATATE. ...Clinical studies are warranted to confi …
In this preclinical study, the SSTR2 antagonist OPS201 (DOTA-JR11; DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH(2)]) labeled wit …
Commentary.
Lu CM. Lu CM. Clin Chem. 2012 Oct;58(10):1406-7. doi: 10.1373/clinchem.2012.182196. Clin Chem. 2012. PMID: 23024129 No abstract available.
Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC.
Hänscheid H, Hartrampf PE, Schirbel A, Buck AK, Lapa C. Hänscheid H, et al. Eur J Nucl Med Mol Imaging. 2021 Jan 15. doi: 10.1007/s00259-020-05177-z. Online ahead of print. Eur J Nucl Med Mol Imaging. 2021. PMID: 33452632
It was tested in selected patients whether the substance is superior to [(177)Lu]Lu-DOTA-TOC. METHODS: Activity kinetics in organs and tumours after [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC were compared intraindividually in five …
It was tested in selected patients whether the substance is superior to [(177)Lu]Lu-DOTA-TOC. METHODS: Activity kinetics in or …
The protective role of lutein on isoproterenol-induced cardiac failure rat model through improving cardiac morphology, antioxidant status via positively regulating Nrf2/HO-1 signalling pathway.
Ouyang B, Li Z, Ji X, Huang J, Zhang H, Jiang C. Ouyang B, et al. Pharm Biol. 2019 Dec;57(1):529-535. doi: 10.1080/13880209.2019.1649436. Pharm Biol. 2019. PMID: 31411934 Free PMC article.
Group I (control) rats were administered with olive oil, Group II (LU) rats were orally pre-treated with only 40 mg of LU for 28 days, Group III (MI induced) rats were injected (subcutaneously; s.c) with 85 mg/kg of ISO for 2 consecutive days, whereas Group IV (L
Group I (control) rats were administered with olive oil, Group II (LU) rats were orally pre-treated with only 40 mg of LU for …
226,183 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page